Reaction

Invasive Ductal Breast Carcinoma reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,687 reports · 74 co-occurring drugs

As of the last recalculation, Invasive Ductal Breast Carcinoma appears in 2,687 FAERS reports alongside 74 co-occurring drug terms. The strongest observed disproportionality signal is LETROZOLE TABLETS (PRR 35.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Letrozole Tablets	205	35.7	35.8
Letrozole	241	33.2	33.3
Exemestane	84	31.3	31.4
Fulvestrant	124	30.4	30.5
Goserelin	51	30.0	30.1
Anastrozole Tablets	72	26.7	26.8
Conjugated Estrogens And Medroxyprogesterone Acetate	62	20.8	20.9
Anastrozole	91	19.8	19.9
Trastuzumab	159	19.0	19.1
Ribociclib	75	18.9	18.9
Pertuzumab	64	18.7	18.7
Lapatinib	36	18.2	18.2
Docetaxel Anhydrous	146	17.7	17.7
Docetaxel	146	17.7	17.7
Everolimus Tablets	32	14.9	15.0
Testosterone	38	12.8	12.8
Zoledronic Acid	63	12.4	12.4
Paclitaxel (Aibumin-Bound)	126	12.4	12.4
Ado-Trastuzumab Emtansine	13	12.0	12.0
Estrogens, Conjugated	83	11.1	11.2
Conjugated Estrogens	81	11.1	11.1
Paclitaxel	132	10.8	10.8
Medroxyprogesterone Acetate	67	10.7	10.7
Cladribine	13	10.5	10.5
Capecitabine	119	10.5	10.5
Doxorubicin Hydrochloride	39	9.4	9.4
Ocrelizumab	72	9.2	9.2
Everolimus	57	8.8	8.9
Natalizumab	189	8.6	8.6
Doxorubicin	95	8.5	8.5
Melphalan	23	7.9	7.9
Fingolimod Hcl	85	7.8	7.8
Estradiol Gel 0.1%	44	7.7	7.7
Estradiol Transdermal	44	7.6	7.7
Baricitinib	9	7.3	7.3
Melphalan Hydrochloride	23	7.2	7.2
Dimethyl Fumarate	104	6.8	6.8
Cyclophosphamide Injection, Solution	147	6.7	6.8
Cyclophosphamide	147	6.7	6.8
Cyclophosphamide For Injection	147	6.7	6.8
Gemcitabine Hydrochloride	45	6.7	6.7
Gemcitabine	33	6.6	6.6
Meclizine Hydrochloride	16	6.4	6.4
Estradiol	69	6.3	6.3
Palbociclib	74	6.2	6.2
Prochlorperazine Maleate	7	5.9	5.9
Progesterone	15	5.1	5.1
Modafinil	20	4.8	4.8
Peginterferon Beta-1A	8	4.7	4.7
Dalfampridine	43	4.7	4.7
Carboplatin	73	4.5	4.6
Ustekinumab	56	4.3	4.3
Fluorouracil	42	4.3	4.3
Fluorouracil Cream, 0.5%	41	4.2	4.2
Interferon Beta-1A	101	4.2	4.2
Carboxymethylcellulose Sodium	5	4.1	4.1
Imatinib	9	4.0	4.0
Denosumab	98	3.9	3.9
Golimumab	41	3.7	3.7
Alpelisib	4	3.6	3.6
Ofatumumab	15	3.5	3.5
Abemaciclib	9	3.5	3.5
Siponimod	4	3.5	3.5
Diroximel Fumarate	5	3.3	3.3
Levonorgestrel	76	3.0	3.0
Olaparib	7	2.6	2.6
Glatiramer Acetate	19	2.5	2.5
Ranitidine Hydrochloride	17	2.4	2.4
Axicabtagene Ciloleucel	3	2.4	2.4
Aflibercept	8	2.0	2.0
Lenalidomide	89	1.7	1.7
Guselkumab	7	1.5	1.5
Ixekizumab	7	1.5	1.5
Etonogestrel	9	1.5	1.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.